The principal investigator has a significant record in research that is both patient-oriented, and translational. A unique and important aspect of his career for the purposes of the K-24 Research Career Award is his continuous involvement with specific interventions beginning with pre-clinical work in the laboratory, and carrying through phases I, II, and III clinical trials. His primary research interest is in the study and development of new therapeutic agents that enhance the cell killing effects of radiation in cancer treatment. Current research projects involve bench studies of 4 agents that enhance the effects of radiation therapy-docetaxel, RFS-2000, RSR-13, and JM-216, all of which act by distinctly different mechanisms. Some studies involve a single agent and radiation therapy, while others involve a combination of chemotherapeutic agents together with radiation. Clinical studies involve three phase I studies of concurrent radiosensitizing agents and radiation therapy - docetaxel, irinotecan, and JM-216. One phase II study involves the allosteric modifier, RSR-13 and radiation therapy. All studies have been continuously supported through private pharmaceutical firm funding, and will continue to be so for the foreseeable future. He has initiated and stimulated a clinical research program in radiation oncology at the Vanderbilt Cancer Center, and was named Director of Clinical Research. Mentoring activities have been a consistent theme throughout his career, both at Brown University and at Vanderbilt. He initiated a fellowship program in radiation oncology clinical research using private funding, and has recruited 3 fellows into the program. Current mentoring activities involve 3 new faculty in the Vanderbilt Cancer Center. He initiated a mixed specialty symposium conference in concomitant chemoradiotherapy, which is continuing as a biennial conference. The K-24 Research Career Award will give the PI an opportunity to concentrate efforts on currently active clinical research projects, moving bench studies through to clinical trials, completing currently active clinical trials, and initiating studies on promising new agents.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
5K24CA082117-02
Application #
6173569
Study Section
Subcommittee G - Education (NCI)
Program Officer
Gorelic, Lester S
Project Start
1999-09-30
Project End
2004-09-29
Budget Start
2000-09-30
Budget End
2001-09-29
Support Year
2
Fiscal Year
2000
Total Cost
$102,861
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Choy, Hak; Schwartzberg, Lee S; Dakhil, Shaker R et al. (2013) Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer. J Thorac Oncol 8:1308-16
Mukhopadhyay, Partha; Ali, M Aktar; Nandi, Animesh et al. (2006) The cyclin-dependent kinase 2 inhibitor down-regulates interleukin-1beta-mediated induction of cyclooxygenase-2 expression in human lung carcinoma cells. Cancer Res 66:1758-66
Kim, Jae-Chul; Ali, M Aktar; Nandi, Animesh et al. (2005) Correlation of HER1/EGFR expression and degree of radiosensitizing effect of the HER1/EGFR-tyrosine kinase inhibitor erlotinib. Indian J Biochem Biophys 42:358-65
Weinberg, Rebecca; Kaurin, Darryl G L; Choy, Hak et al. (2004) Dosimetric uncertainties of three-dimensional dose reconstruction from two-dimensional data in a multi-institutional study. J Appl Clin Med Phys 5:15-28
Kim, Jae-Chul; Saha, Debabrata; Cao, Qianwen et al. (2004) Enhancement of radiation effects by combined docetaxel and flavopiridol treatment in lung cancer cells. Radiother Oncol 71:213-21
Saha, Debabrata; Sekhar, Konjeti R; Cao, Carolyn et al. (2003) The antiangiogenic agent SU5416 down-regulates phorbol ester-mediated induction of cyclooxygenase 2 expression by inhibiting nicotinamide adenine dinucleotide phosphate oxidase activity. Cancer Res 63:6920-7
Saha, Debabrata; Pyo, Hongryull; Choy, Hak (2003) COX-2 inhibitor as a radiation enhancer: new strategies for the treatment of lung cancer. Am J Clin Oncol 26:S70-4
Kim, Jae Sung; Amorino, George P; Pyo, Hongryull et al. (2002) Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells. Radiother Oncol 62:61-7
Pyo, H; Choy, H; Amorino, G P et al. (2001) A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res 7:2998-3005
Choy, H; DeVore, R F; Hande, K R et al. (2001) Phase I trial of outpatient weekly docetaxel, carboplatin and concurrent thoracic radiation therapy for stage III unresectable non-small-cell lung cancer: a Vanderbilt cancer center affiliate network (VCCAN) trial. Lung Cancer 34:441-9

Showing the most recent 10 out of 13 publications